We are live on
!
Find out more
PCM
Pathway Capital Management Portfolio holdings
AUM
$4.3M
1-Year Est. Return
62.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.78%
1 Year Est. Return
+62.8%
3 Year Est. Return
+496.35%
5 Year Est. Return
+305.57%
10 Year Est. Return
–
AUM
$29.1M
AUM Growth
-$26.9M
(-48%)
Cap. Flow
-$27.2M
Cap. Flow
% of AUM
-93.57%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
3
Increased
–
Reduced
–
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UiPath
PATH
|
+$4.6M |
| 2 |
Amplitude
AMPL
|
+$2.78M |
| 3 |
Airbnb
ABNB
|
+$355K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$21.4M |
| 2 |
ACLX
Arcellx
ACLX
|
+$5.86M |
| 3 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$3.67M |
| 4 |
TransDigm Group
TDG
|
+$2.85M |
| 5 |
Flywire
FLYW
|
+$1.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 98.67% |
| 2 | Consumer Discretionary | 1.33% |
| 3 | Healthcare | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Toast
TOST
$17.4B
| $20.7M | 71.33% |
1,168,871
| – | – |
|
|
2
UiPath
PATH
$6.3B
| $5.35M | 18.38% |
+304,415
| New | +$4.6M |
|
|
3
Amplitude
AMPL
$1.27B
| $2.61M | 8.97% |
+209,694
| New | +$2.78M |
|
|
4
Airbnb
ABNB
$86.6B
| $387K | 1.33% |
+3,110
| New | +$355K |
|
|
ACLX
5
DELISTED
Arcellx
ACLX
| – | – |
-189,120
| Closed | -$5.86M |
|
|
DAWN
6
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-995,686
| Closed | -$21.4M |
|
|
7
Flywire
FLYW
$2.24B
| – | – |
-46,960
| Closed | -$1.15M |
|
|
8
TransDigm Group
TDG
$67.9B
| – | – |
-4,530
| Closed | -$2.85M |
|
|
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-245,606
| Closed | -$3.67M |
|
Similar funds
CC
RA
ABA
UOMF
EAMS
KAM
FWA
RCP
Pathway Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Pathway Capital Management held 9 positions worth $29.1M, down 48% from $56M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Pathway Capital Management withdrew a net $27.2M in Q1 2023, closing 5 positions. Its most notable exit was Day One Biopharmaceuticals, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 99% of assets, up from 40% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Pathway Capital Management opened a new position in UiPath worth $5.35M.
- Pathway Capital Management's largest Q1 2023 buy was UiPath: 304,415 shares worth $5.35M.
- Pathway Capital Management fully exited Day One Biopharmaceuticals in Q1 2023, selling an estimated $21.4M.
- Pathway Capital Management's ten largest holdings make up 100% of its $29.1M portfolio in Q1 2023.
- Pathway Capital Management opened 3 new positions and closed 5 in Q1 2023.
- Pathway Capital Management's portfolio value fell 48% quarter-over-quarter to $29.1M.
Based on Pathway Capital Management's 13F filing for Q1 2023, filed 10 May 2023.